publication date: Mar. 23, 2018

In Brief

Robert Redfield to be named CDC director

Robert Redfield is expected to be named the 18th Director of the Centers for Disease Control and Prevention and Administrator of the Agency for Toxic Substances and Disease Registry.

He is to replace Brenda Fitzgerald, who was forced out after Politico reported that she bought tobacco company stock after accepting the top job at CDC.

The job doesn’t require Senate confirmation.

Redfield has been engaged in clinical research and clinical care of chronic human viral infections and infectious diseases, especially HIV, for more than 30 years. He served as the founding director of the Department of Retroviral Research within the U.S. Military’s HIV Research Program, and retired after 20 years of service in the U.S. Army Medical Corps.

Following his military service, Redfield co-founded the University of Maryland Institute of Human Virology with William Blattner and Robert C. Gallo and served as the chief of Infectious Diseases and vice chair of Medicine at the University of Maryland School of Medicine.

Redfield made several early contributions to the scientific understanding of HIV, including the demonstration of the importance of heterosexual transmission, the development of the Walter Reed staging system for HIV infection, and the demonstration of active HIV replication in all stages of HIV infection.  

In addition to his research work, Redfield oversaw an extensive clinical program providing HIV care and treatment to more than 5,000 patients in the Baltimore/Washington, D.C. community.

Redfield served as a member of the President’s Advisory Council on HIV/AIDS from 2005 to 2009, and was appointed chair of the international subcommittee from 2006 to 2009.

He is a … Continue reading Robert Redfield to be named CDC director

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.